Enjoy complimentary customisation on priority with our Enterprise License!
This market research study analyzes the leading players in the global next-generation biologics market such as Biogen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals. A competitive analysis of this market is also presented by therapies (next-generation regenerative medicine, next-generation antibodies, next-generation insulin products, next-generation recombinant coagulation factors) and by geography (the Americas, APAC, and EMEA).
According to the next generation biologics market analysis, the market is anticipated to witness staggering growth and will post a staggering CAGR of more than 14% during the forecast period. The increasing demand for antibody drug conjugates (ADCs) is one of the major factors driving this market’s growth. ADCs are highly effective cytotoxic drugs linked to a mAbs. These drugs have shown to be potent and efficient in treating diseases, including cancers and hematological malignancies. Therefore, in recent years, antibodies have become the preferred choice to treat respiratory, oncology, and inflammatory diseases.
The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, has increased significantly. The augmented use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to market growth.
One of the recent trends gaining traction in the market is the emergence of targeted and combination therapies for the treatment of various diseases such as viral infections and cancer. This is mainly because targeted therapies have fewer side effects than conventional non-targeted therapies. Combination therapies work by targeting multiple mechanisms simultaneously. Targeting multiple pathways in diseases such as cancer, reduce the risk of developing treatment-resistant disorders. As a result, combination therapies, which target distinct mechanisms, are highly efficacious in treating various diseases, which will boost this market’s growth over the next four years.
The global next generation biologics market is highly competitive owing to the presence of well-established vendors like F. Hoffmann-La Roche, Sanofi, and Biogen. The entry of these emerging firms is likely to intensify the competition, both regarding innovation and technology during the forecast period. The growth opportunities present in the market also enable the entry of new players.
The next-generation regenerative medicine segment led the market and is expected to dominate the market in the coming years. This segment’s growth is attributed to the increasing demand for tissue-engineered and stem cell products for the treatment of various diseases. Other major factors driving the demand for regenerative products are the increasing government funding in R&D, rising prevalence of chronic diseases, and increasing focus of vendors on cell therapy products.
In terms of geography, the next-generation biologics market in the Americas was the fastest growing among other regions and will dominate the market over the next four years. The accelerated approvals for certain formulations will significantly boost this market’s growth in the region. For example, the US FDA granted accelerated approval to daratumumab (DARZALEX) injection for the treatment of multiple myelomas in November 2015. Moreover, the increasing prevalence of cancer, autoimmune diseases, metabolic disorders, and blood disorders in the region will also propel this market’s growth in the Americas until the end of 2020.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by application
PART 07: Geographical segmentation
PART 08: Market drivers
PART 09: Impact of drivers
PART 10: Market challenges
PART 11: Impact of drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
PART 16: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.